Loading
companiesCompany
Ibex Medical Analytics
Ibex makes artificial intelligence that examines digitised biopsy slides to help pathologists detect and grade prostate, breast and stomach cancer, and to score biomarkers such as HER2. Its prostate tool is FDA cleared and its systems are used in hundreds of laboratories.
Overview
Ibex Medical Analytics, founded in Tel Aviv in 2016 and now dated from Boston, Massachusetts, develops clinical-grade AI for cancer pathology. Its platform (Galen, now Ibex 4) detects cancer and over a hundred diagnostic features across tissue types: Ibex Prostate for detection and Gleason grading, Ibex Breast for diagnosis, grading and HER2 scoring, and Ibex Gastric. Models were trained on more than 10 million slides and about 2.4 million slides a year are analysed across hundreds of live sites. Ibex Prostate Detect received FDA 510(k) clearance in February 2025 as a second-read device for missed prostate cancers in core biopsies; HER2 scoring and breast IHC panels are CE-IVDR certified. Deployments include UPMC, a national rollout in Wales and Alverno Laboratories and partners include Philips, Fujifilm and Roche. The $55 million Series C in September 2023 was led by 83North.
Headquarters
Boston, MA, US
Funding
All startupsGrowth stage
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Series C · Led by 83North, September 2023; cumulative funding over $100 million. | 2023 | $55M | ibex-ai.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Growth stage
Website
Founded
2016
Notes
top- Series C release (2023) is dated Tel Aviv; 2025 and 2026 releases are dated Boston, MA, so Boston is used as HQ with Tel Aviv as founding location and R&D base.
Similar pages
- JournalAnalytical cellular pathology (Amsterdam)
Shares Digital pathology & AI, Histopathology & immunohistochemistry.
- CompanyHistoWiz
Shares Digital pathology & AI, Histopathology & immunohistochemistry.
- CompanyDigistain
Shares Digital pathology & AI, Histopathology & immunohistochemistry.
- TechnologyAI scoring of biomarkers and grade on pathology slides
Shares Digital pathology & AI, HER2-positive breast cancer, Prostate cancer.
- CompanyAtaraxis AI
Shares Companion diagnostics, Digital pathology & AI, HER2-positive breast cancer.
- CompanyImagene AI
Shares Companion diagnostics, Digital pathology & AI, HER2.
- CompanyX-Zell
Shares Digital pathology & AI, Prostate cancer.
- CompanyPerimeter Medical Imaging AI
Software in use
The software of oncology →Commercial and regulated products that this organisation sells. Each card says what is behind it: a regulator's database, the literature, a public body's list, or only the company's own words. Listing is not endorsement, and a clearance is a regulatory fact, not a clinical one.
A second-read algorithm over scanned biopsy slides that marks cases the laboratory should look at again before the report goes out.
Ibex Medical AnalyticsFDA K241232